Table of Contents Author Guidelines Submit a Manuscript
Evidence-Based Complementary and Alternative Medicine
Volume 2013, Article ID 969824, 9 pages
http://dx.doi.org/10.1155/2013/969824
Research Article

Electroacupuncture and Rosiglitazone Combined Therapy as a Means of Treating Insulin Resistance and Type 2 Diabetes Mellitus: A Randomized Controlled Trial

1Department of Internal Medicine and Emergency Medicine, Division of Endocrinology and Metabolism, Tungs’ Taichung Metro Harbor Hospital, Taichung County, Taiwan
2Department of Traditional Chinese Medicine, China Medical University Hospital, Taichung City, Taiwan
3Department of Acupuncture, China Medical University Hospital, Taichung City, Taiwan
4Department of Orthopedics, Taichung Veterans General Hospital, Taichung City, Taiwan
5College of Life Science, National Tsing Hua University, Hsinchu City, Taiwan
6Department of Traditional Chinese Medicine, En Chu Kong Hospital, Taipei, Taiwan
7Division of Traditional Chinese Medicine, Chia-Yi Christian Hospital, Chiayi City, Taiwan
8Department of Medicinal Botanicals and Health Applications, Da-Yeh University, Changhua County 51591, Taiwan
9School of Chinese Medicine for Post-Baccalaureate, I-SHOU University, Kaohsiung County, Taiwan
10School of Chinese Medicine, China Medical University, Taichung City, Taiwan

Received 21 February 2013; Revised 19 April 2013; Accepted 28 April 2013

Academic Editor: Gerhard Litscher

Copyright © 2013 Rong-Tsung Lin et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Aims. To evaluate the efficacy of rosiglitazone (TZD) and electroacupuncture (EA) combined therapy as a treatment for type 2 diabetes mellitus (T2DM) patients by randomized single-blind placebo controlled clinical trial. Methods. A total of 31 newly diagnostic T2DM patients, who fulfilled the study's eligibility criteria, were recruited. The individuals were randomly assigned into two groups, the control group (TZD, ) and the experimental group (TZD + EA, ). Changes in their plasma free fatty acid (FFA), glucose, and insulin levels, together with their homeostasis model assessment (HOMA) indices, were statistically compared before and after treatment. Hypoglycemic activity (%) was also compared between these two groups. Results. There was no significant difference in hypoglycemic activity between the TZD and TZD + EA group. The effectiveness of the combined therapy seems to derive from an improvement in insulin resistance and a significant lowering of the secreted insulin rather than the effect of TZD alone on T2DM. The combined treatment had no significant adverse effects. A lower plasma FFA concentration is likely to be the mechanism that causes this effect. Conclusion. This combined therapy seems to suppress endogenous insulin secretion by improving insulin resistance via a mechanism involving a reduction in plasma FFA. This trial is registered with ClinicalTrials.gov NCT01577095.